Intravenous beta-adrenoblocker therapy in acute coronary syndrome patients

Early treatment optimization improves clinical outcomes and reduces morbidity and mortality in patients with acute myocardial infarction (AMI). Intravenous beta-adrenoblocker (BAB) therapy, associated with improved survival, is well tolerated by AMI patients. The results of relevant clinical trials...

Full description

Saved in:
Bibliographic Details
Main Authors: S. N. Tereshchenko, I. V. Zhirov
Format: Article
Language:Russian
Published: «SILICEA-POLIGRAF» LLC 1970-01-01
Series:Кардиоваскулярная терапия и профилактика
Subjects:
Online Access:https://cardiovascular.elpub.ru/jour/article/view/1497
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849342118867238912
author S. N. Tereshchenko
I. V. Zhirov
author_facet S. N. Tereshchenko
I. V. Zhirov
author_sort S. N. Tereshchenko
collection DOAJ
description Early treatment optimization improves clinical outcomes and reduces morbidity and mortality in patients with acute myocardial infarction (AMI). Intravenous beta-adrenoblocker (BAB) therapy, associated with improved survival, is well tolerated by AMI patients. The results of relevant clinical trials are presented. The causes of possible increase in cardiogenic shock risk for metoprolol group, COMMIT trial, are analyzed. Evidence base for early BAB therapy in AMI patients is presented.
format Article
id doaj-art-0d6a235be87f4c8eb42da1a60dde50ac
institution Kabale University
issn 1728-8800
2619-0125
language Russian
publishDate 1970-01-01
publisher «SILICEA-POLIGRAF» LLC
record_format Article
series Кардиоваскулярная терапия и профилактика
spelling doaj-art-0d6a235be87f4c8eb42da1a60dde50ac2025-08-20T03:43:29Zrus«SILICEA-POLIGRAF» LLCКардиоваскулярная терапия и профилактика1728-88002619-01251970-01-017790941215Intravenous beta-adrenoblocker therapy in acute coronary syndrome patientsS. N. Tereshchenko0I. V. Zhirov1Moscow State Medico-Stomatological University, State Federal Agency for Health and Social Development, MoscowMoscow State Medico-Stomatological University, State Federal Agency for Health and Social Development, MoscowEarly treatment optimization improves clinical outcomes and reduces morbidity and mortality in patients with acute myocardial infarction (AMI). Intravenous beta-adrenoblocker (BAB) therapy, associated with improved survival, is well tolerated by AMI patients. The results of relevant clinical trials are presented. The causes of possible increase in cardiogenic shock risk for metoprolol group, COMMIT trial, are analyzed. Evidence base for early BAB therapy in AMI patients is presented.https://cardiovascular.elpub.ru/jour/article/view/1497acute myocardial infarctionbeta-adrenoblockerscardiogenic shockgenetic polymorphism
spellingShingle S. N. Tereshchenko
I. V. Zhirov
Intravenous beta-adrenoblocker therapy in acute coronary syndrome patients
Кардиоваскулярная терапия и профилактика
acute myocardial infarction
beta-adrenoblockers
cardiogenic shock
genetic polymorphism
title Intravenous beta-adrenoblocker therapy in acute coronary syndrome patients
title_full Intravenous beta-adrenoblocker therapy in acute coronary syndrome patients
title_fullStr Intravenous beta-adrenoblocker therapy in acute coronary syndrome patients
title_full_unstemmed Intravenous beta-adrenoblocker therapy in acute coronary syndrome patients
title_short Intravenous beta-adrenoblocker therapy in acute coronary syndrome patients
title_sort intravenous beta adrenoblocker therapy in acute coronary syndrome patients
topic acute myocardial infarction
beta-adrenoblockers
cardiogenic shock
genetic polymorphism
url https://cardiovascular.elpub.ru/jour/article/view/1497
work_keys_str_mv AT sntereshchenko intravenousbetaadrenoblockertherapyinacutecoronarysyndromepatients
AT ivzhirov intravenousbetaadrenoblockertherapyinacutecoronarysyndromepatients